ReposiTrak (TRAK) has reported Q3 2026 revenue of about US$5.9 million with basic EPS of roughly US$0.11, against a trailing 12 month EPS figure of about US$0.39 that reflects earnings growth of 11.5% over the past year and 17% per year over five years. Over recent quarters, the company has seen revenue move around the US$5.5 million to US$6.0 million range while quarterly EPS has tracked between roughly US$0.08 and US$0.11, supported by trailing 12 month net income of about US$7.1 million. With net profit margins reported at 30.1% and higher than last year, these results point to a business that is currently leaning on margin strength as a key pillar of its story.

See our full analysis for ReposiTrak.

With the latest numbers on the table, the next step is to weigh them against the most common narratives around ReposiTrak to see which stories fit the data and which ones start to look stretched.

30.1% net margin and EPS trend in focus

• Over the last 12 months, ReposiTrak generated about US$23.5 million in revenue and US$7.1 million in net income, which works out to a 30.1% net margin compared with 28.8% a year earlier.
• Consensus narrative points to traceability demand and automation as key margin drivers, and the current 30.1% margin together with trailing 12 month EPS of roughly US$0.39 shows the business already operating at the high profitability levels that bulls expect, even as one year earnings growth of 11.5% sits below the 17% per year five year pace.
  • Supporters highlight automation and partnerships as helping efficiency, which lines up with margins above 30% on about US$23.5 million of trailing revenue.
  • At the same time, the slower 11.5% one year earnings growth compared with 17% per year over five years means the bullish view has to assume that the margin strength is durable even if the growth rate has cooled.

TTM profit growth vs slower near term pace

• Trailing 12 month earnings of about US$7.1 million have been built on several quarters of net income in the US$1.6 million to US$2.0 million range, with basic EPS moving between roughly US$0.08 and US$0.11 per quarter.
• Analysts' consensus view expects earnings to grow about 14.1% per year and revenue about 8.7% per year, and that creates a tension where multi year earnings growth of 17% per year and a current margin of 30.1% look solid, while the latest 11.5% one year earnings growth rate and the below market forecast growth rates suggest a steadier, more moderate path than some of the more optimistic double digit revenue targets mentioned in the broader narrative.
  • The forecast 14.1% earnings growth sits between the recent 11.5% one year outcome and the 17% per year five year history, so the consensus view effectively assumes a middle ground rather than a re acceleration.
  • Expected revenue growth of 8.7% per year, which is below the 11.7% figure cited for the broader US market, indicates that any future upside in the story may need to come from holding margins near current levels rather than outpacing market revenue growth.

DCF fair value gap and analyst target

• The shares last traded around US$9.70, compared with a DCF fair value of about US$11.72 and an analyst price target of US$16.00, while the stock trades on a 24.9x P/E that sits slightly under the 25.2x peer average and the 28.5x US software industry average.
• Bears argue that growth risks around FDA traceability enforcement, rising operating expenses and competition could make these valuation reference points harder to justify, and the current forecasts, which call for earnings growth of about 14.1% per year and revenue growth of 8.7% per year, show that even the provided growth outlook is already below the referenced US market earnings growth of 16.7% and revenue growth of 11.7%.
  • Critics highlight that if operating expenses rise faster than revenue, the 30.1% net margin underpinning the current 24.9x P/E and the US$11.72 DCF fair value could come under pressure.
  • Competitive threats from retailers handling traceability internally or via alternative platforms would matter more in a context where revenue growth is already expected to trail the broader market, which is part of why the US$16.00 analyst target and the DCF fair value need careful scrutiny against personal assumptions.

Skeptics who want to see how these risks are framed against the current P/E and fair value gap can dig into the full bear case in 🐻 ReposiTrak Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for ReposiTrak on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Given the mix of confident and cautious signals in the story so far, now is a good time to look through the numbers yourself and stress test your view against the company specific positives that investors are watching. To see which features the market currently treats as potential bright spots, review the 3 key rewards.

See What Else Is Out There

ReposiTrak's story leans heavily on strong 30.1% margins while its recent 11.5% earnings growth and forecast revenue growth sit below broader market expectations.

If that slower growth profile gives you pause, use the 49 high quality undervalued stocks to quickly spot companies where valuations may already compensate for more modest outlooks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.